MedTrace Logo

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

NCT03515980 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2020-08-27

No results posted yet for this study

Summary

This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.

Conditions

  • Liver Dysfunction
  • Liver Insufficiency
  • Hepatic Failure
  • Myocardial Failure
  • Cardiac Failure
  • Congestive Heart Failure
  • Heart Decompensation

Interventions

DRUG

BMS-986231

Intravenous (IV) administration

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2019-08-29
Completion
2019-08-29
FDA Drug
Yes

Countries

  • Hungary
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515980 on ClinicalTrials.gov